Alcon AG vs Strategy Inc. — how do they compare? Alcon AG trades at $75 (market cap $35.19B), while Strategy Inc. trades at $96.62 (market cap $38.33B). The key difference: Alcon AG and Strategy Inc. are close in size by market cap, and Alcon AG pays a 0.49% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| ALC | MSTR | |
|---|---|---|
Market Cap | $35.19B | $38.33B |
Sector | Health | Technology |
52-Week High | $90.12 | $394.39 |
52-Week Low | $62.02 | $82.31 |
Enterprise Value | $39.03B | $57.09B |
Dividend Yield | 0.49% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
MSTR trades at $100.01, up 3.26% today, with a bullish technical signal despite recent earnings misses. The company reported Q2 2026 EPS of -$24.45 versus -$2.19 expected, continuing a trend of negative profitability. Analyst consensus remains positive with a $210 price target, though fundamentals show significant challenges including a negative net income margin of -6,102.96% and substantial Bitcoin-related investment outflows.
The outlook is mixed: strong analyst support suggests upside potential, but fundamental weaknesses and persistent earnings misses pose substantial risks. Investment opportunity exists if the company can leverage its cash position for growth, while risks include continued operational losses and dependence on Bitcoin market performance.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →